Kopran Ltd(KOPRAN)

NSE: KOPRANBSE: 524280

₹ 248.95+0.77%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 1,203 crWebsite: www.kopran.comUpdated: 27 Oct 2026

About

Kopran Ltd is a pharmaceutical company with two businesses: active pharmaceutical ingredients (APIs), run through KRLL, and finished formulations sold entirely to export markets. FY26 revenue was 681.42 (Rs crore), of which the API business contributed Rs 37,335 lakh and formulations Rs 29,639 lakh. Its key API segments are carbapenems and anti-hypertensives.^[1][2]

Business segments

API business (KRLL): revenue of Rs 9,538 lakh in Q1 FY27, against Rs 37,335 lakh for the whole of FY26.^[2]
Formulations: revenue of Rs 5,709 lakh in Q1 FY27, against Rs 29,639 lakh for FY26. All formulations sales are exports.^[2]
Segment revenue for FY25: API Rs 35,881 lakh and formulations Rs 26,249 lakh.^[3]

Products

The company has commercialised 26 API products. Carbapenems and anti-hypertensives are its key API segments.^[2]
Formulations are made at two plants, one for penicillin products and one for non-penicillin products. In Q3 FY26 the non-penicillin plant sold Rs 5,491 lakh and the penicillin plant Rs 3,740 lakh.^[4]

Exports and markets

API export sales were Rs 5,677 lakh in Q1 FY27, compared with Rs 3,544 lakh in Q1 FY26.^[2][3]
API sales in Q3 FY26: exports Rs 6,748 lakh and local sales Rs 3,257 lakh, for a total of Rs 10,005 lakh.^[4]
Formulations are sold to both regulated and non-regulated export markets, including Africa, the UK, Canada, MENA and Southeast Asia.^[5][3]
As of FY26, the formulations business held regulatory approvals in 15 countries.^[5]

Quarterly operating trend

Revenue from operations was Rs 15,399 lakh in Q1 FY27, up from Rs 13,522 lakh in Q1 FY26 and down from Rs 23,402 lakh in Q4 FY26.^[2]
EBITDA margin was 10.31% in Q1 FY27, against 17.38% in Q4 FY26 and 10.57% in Q1 FY26.^[2]
EBITDA margin fell to 2.51% in Q2 FY26 and recovered to 10.42% in Q3 FY26. The Q3 FY25 margin was 13.78%.^[4]

Expansion and capex

The company is setting up an API and R&D facility at Panoli, Gujarat, to expand capacity. No investment amount or completion date has been disclosed.^[2][3]
Net fixed assets were Rs 37,780 lakh at Q1 FY27, up from Rs 37,124 lakh at the end of FY26 and Rs 32,160 lakh at the end of FY25.^[2]
Depreciation was Rs 577 lakh in Q1 FY27, up from Rs 426 lakh in Q1 FY26, as capex was capitalised.^[2]

Strategy

The company aims to lower costs by making its own API intermediates (cutting reliance on China), improving yields and automating packing lines.^[2]
It is pursuing new customers, new geographies and new regulatory filings, and selling new products to existing customers.^[2][5]

Market Cap

₹1,203 Cr

High / Low

₹296 / 107

Stock P/E

47.4

Price / Book

2.2

Book Value

₹110

EPS

₹5.3

No. of Shares

4.83 Cr

ROCE

6.5%

ROE

4.9%

OPM

6.6%

Debt / Equity

0.29

Sales

₹681 Cr

Net Profit

₹26 Cr

Promoter holding

41.8%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials